The efficacy of social marketing campaigns in facilitating a societal shift in beliefs and attitudes towards low back pain (LBP) is well established. Evidence suggests that campaigns need to be exhaustive and utilise multimedia. The Spinal Pain Model of Care recommends the use of social marketing strategies in WA, specifically mass media campaigns. Development of a single, Government-issued resource which delivers simple, evidence-based messages to the public about active pain management strategies for LBP is the first step in developing a suite of social marketing resources for minimising the burden of spinal pain in WA.
Aim
The aim of this project is to undertake an evaluation of the LBP pamphlet within a primary care context. The SPIWG will partner with Curtin University and the Pharmaceutical Society of Australia (WA) (PSA-WA) for the evaluation. The project will determine whether providing the pamphlet to individuals who visit a community pharmacy to purchase pain-relieving medications for LBP is effective in improving beliefs about LBP and minimising fear avoidance behaviours related to LBP, compared to not providing the pamphlet. A secondary aim is to determine whether providing the pamphlet with the pharmacist reiterating the key messages to the consumer is more effective than providing the pamphlet alone.
Design
A randomized, controlled trial, consisting of 3 study arms (A, B and C), will be undertaken in partnership with 20 community pharmacies in the Perth metropolitan area. A convenience sample of pharmacies will be selected through the PSA-WA.
Participating pharmacies will cover major zones of the Perth metropolitan area to represent a range of socioeconomic levels. Ten pharmacies will be involved in both the 'control' (A) and 'pamphlet only' (B) arms while a separate ten pharmacies will be involved in the 'pamphlet with education' (C) arm only. Pharmacies will be allocated to study groups randomly. Each pharmacist who participates in the workshop, will receive training from the evaluation team according to their allocated study arm and remuneration for recruitment.
Participants
Pharmacists and/or pharmacy staff will identify individuals who present to the pharmacy to purchase pain-relieving medications for LBP by:
asking customers about the reason for their medication purchase or GP medicine prescription;
ii) answering questions from customers about medication options for LBP or;
iii) customers approaching pharmacy staff about the study in response to posters placed in the pharmacy which advertise the study.
Any pharmacy customer aged 18-70 years who is currently experiencing low back pain and has adequate understanding of written and spoken English is eligible to participate. There are no exclusion criteria for this study. Each pharmacy will recruit 12 consecutive customers who meet the inclusion criteria for each study arm. The total sample size will therefore be N=360. Customers who are interested in participating will be asked to complete a consent form and a baseline questionnaire.
The completed form and questionnaire will be sent by the pharmacy to Curtin University in a reply paid envelope.
Outcome measures
Data will be collected at baseline (T0) and then at 2 weeks (T1), and 8 weeks (T2) after the intervention. Table 1 shows which outcomes measures will be measured at particular time points. Beliefs about back pain will be collected using the Back Pain
Beliefs Questionnaire and fear avoidance behaviours will be collected using the Fear Avoidance Beliefs Questionnaire. Pain intensity and disability will be measured using an 11 point numeric rating scale (NRS). Demographic (age, gender, highest level of education) and pain history characteristics (duration of symptoms) will be measured at baseline only while an 11 point NRS for Global Perceived Impression of Usefulness will be used at time points subsequent to baseline to measure the usefulness of the pamphlet. 
Participants will be asked to provide informed consent at baseline, including their contact details and date of birth. All data will be collected using a 2 page, teleform paper questionnaire which will be de-identified but linked to person details using a unique study identifier. Data at T0 will be collected onsite at the pharmacy while follow-up questionnaires (T1, T2) will be posted to participants with a reply-paid envelope. All data will be returned to Curtin University for secure storage and analysis. Participants who do not return follow-up questionnaires will be contacted by a project officer and reminded to do so.
Interventions
Interventions will be phased in the following sequence:
A) Control (pharmacies 1-10): pharmacists will be asked to invite the first 12 customers who meet the inclusion criteria to participate in the study as a control (N=120). In the control arm, customers will not receive any information about selfmanagement for LBP (i.e.; will receive 'usual care' only).
B) Pamphlet only (pharmacies 1-10): pharmacists will be asked to invite the next 12
customers, that is the next 12 customers after the control participants have been recruited, who meet the inclusion criteria, to participate in the study (N=120). In this arm, participants will receive a pamphlet from the pharmacist without any further information about self management, other than usual instructions from the pharmacist relating to medication intake, dosage and side-effects. Baseline data will be collected prior to the pamphlet being provided.
C) Pamphlet with education (pharmacies 11-20):
pharmacists will be asked to invite the first 12 customers who meet the inclusion criteria to participate in the study (N=120). In this arm, participants will receive a pamphlet from the pharmacist and the pharmacist will review the content of the pamphlet with the participant. Information provided by pharmacists will be standardised. Baseline data will be collected prior to the pamphlet and further information being provided. The role of the pharmacist will be to reinforce the key messages contained in the pamphlet Analysis A 3x3 ANOVA with one repeated measure will be used to examine main effects for group (k=3) and time point (k=3), as well as interactions between the factors.
Ethical implications
Approval to conduct the study will be sought from the Human Research Ethics
Committee of Curtin University and the Department of Health (WA).
Staffing
One project officer will be appointed at level 4.1 (Curtin General Staff salary level) at 0.2 FTE for 6 months to coordinate the study and manage the data collection, data entry and data storage processes. Data analysis and report writing will be undertaken by Honours students in Pharmacy and/or Physiotherapy degrees at Curtin University.
Overall management of the study will be undertaken by a member of the project team (yet to be confirmed).
Feasibility
Using a partnership arrangement between Health Networks, Curtin University, Musculoskeletal Health Network and the Pharmaceutical Society of Australia, completion of data collection is feasible within 6 months with a budget of $14,300. It is envisaged that recruitment of participants from 20 pharmacies for each arm of the study will be possible within 4 week blocks; ie 12 participants per pharmacy per 4 week block (3 customers per week). Providing a modest remuneration to each pharmacy will also assist with recruitment.
Budget
Photocopying and postage ($5 per person) $1,500
Design and printing of advertising posters $1,000
Design and printing of teleform sheets for data collection $1,000
Design and printing of 500 pamphlets $500
Training of pharmacists (evening forum) $500
Project officer (0. 
